Medifast Inc

Medifast Inc(MED)股票分析

$12.730

-0.406 (-3.19%)收盘时

Loading chart…
最高
13.220
开盘
13.080
成交量加权均价
12.81
成交量
152.10K
市值
230.99M
最低
12.470
成交额
1.95M
企业价值/息税折旧摊销前利润(TTM)
-1.79

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.

AI 分析 of Medifast Inc (MED)

持有

Medifast Inc (MED) is currently trading at $12.53, showing a recent upward trend with a 5-day change of +3.47%. However, the company has reported significant losses, with a forward P/E of 12.48 indicating potential recovery but also reflecting ongoing challenges. The RSI is at 67.72, suggesting it may be nearing overbought territory. The main risk is the substantial net income loss of $17.5 million reported for Q3 2026, which raises concerns about its financial stability.

分析师评级(2)

买入
1 买入
1 持有
0 卖出
当前: 12.73
最低
—
平均
—
最高
—

Stephens

2026-02-19

目标价

$12

Equal Weight

DA Davidson

2025-02-19

目标价

$17

持有

DA Davidson

2024-11-05

目标价

$17

持有

DA Davidson

2024-07-22

目标价

$18

卖出

DA Davidson

2024-06-05

目标价

$18

卖出

估值指标

Medifast Inc(MED)当前预期市盈率为 12.48,5 年平均预期市盈率为 10.08。

预期市盈率

合理
5 年均值 P/E
10.08
当前P/E
12.48
高估
76.00
低估
-55.84

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
1.60
当前EV/EBITDA
-1.79
高估
15.94
低估
-12.73

预期市销率

合理
5 年均值 P/S
0.72
当前P/S
0.54
高估
1.07
低估
0.37

Alphio AI 对 MED 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MED

$7.77

情景价格

基

基准

基准 · 50%MED

$7.58

情景价格

悲

悲观

悲观 · 25%MED

$5.48

情景价格

事件时间线

2026-10-26 (ET)

08:30:00

Company Expects 2026 Revenue Between $280 Million and $300 Million

08:30:00

Medifast Reports Q3 Revenue of $72.05M

08:30:00

Sees Q4 Revenue of $55M-$75M

2026-08-27 (ET)

09:00:00

Medifast Launches Metabolic Health Institute

2026-08-03 (ET)

19:30:00

Stock Futures Broadly Higher, Oil Prices Slip

资讯

MED 常见问题 —— 由 Alphio AI 解答

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources. It operates in the Consumer Non-Cyclicals sector (MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS industry).

Medifast Inc (MED) is currently trading at $12.53, showing a recent upward trend with a 5-day change of +3.47%. However, the company has reported significant losses, with a forward P/E of 12.48 indicating potential recovery but also reflecting ongoing challenges. The RSI is at 67.72, suggesting it may be nearing overbought territory. The main risk is the substantial net income loss of $17.5 million reported for Q3 2026, which raises concerns about its financial stability.

2 analysts cover MED: 1 rate it Buy, 1 Hold and 0 Sell.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易